Novo Nordisk A/S (NOV)
XDUS
40.05
-0.09 (-0.21%)
Closed
Aug 24, 2026
Day's Range
39.9640.34
52 wk Range
30.2654.74
Financial Statements - NOV - Novo Nordisk A/S
Revenue
309.06B▲ 694.7%
Net Income
102.43B▲ 657.4%Net Margin 33.1%
EBITDA
150.65B▲ 712.7%
Free Cash Flow
28.98B▲ 210.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 309.06B | 38.89B | 232.26B | 176.95B | 140.80B | 126.94B |
| Cost of Goods | 58.78B | 5.96B | 35.76B | 28.44B | 23.65B | 20.93B |
| Gross Profit | 250.27B | 32.92B | 196.49B | 148.50B | 117.14B | 106.01B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 127.65B | 17.18B | 102.57B | 74.80B | 58.64B | 54.12B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 6.06B | -141.55M | 1.77B | -5.42B | 616M | -793M |
| Pre Tax Income | 130.54B | 17.03B | 104.67B | 69.06B | 59.08B | 53.13B |
| Income Tax | 28.10B | 3.50B | 20.99B | 13.53B | 11.32B | 10.99B |
| Net Income | 102.43B | 13.52B | 83.68B | 55.52B | 47.75B | 42.13B |
| EPS Basic | 23.06 | 22.67 | 18.67 | 12.26 | 10.395 | 9.025 |
| EPS Diluted | 23.03 | 22.63 | 18.62 | 12.22 | 10.37 | 9.005 |
| Basic Shares Outstanding | 4.44B | 596.46M | 33.43B | 33.79B | 34.26B | 34.81B |
| Diluted Shares Outstanding | 4.44B | 596.46M | 33.43B | 33.79B | 34.26B | 34.81B |
| Ebit | 134.74B | 17.25B | 105.21B | 69.44B | 59.36B | 53.52B |
| Ebitda | 150.65B | 18.53B | 112.94B | 82.04B | 64.75B | 60.21B |
| Net Income Continuous Operations | 102.43B | 13.52B | 83.68B | 55.52B | 47.75B | 42.13B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
